A Phase II Trial Evaluating the Feasibility of Adding Bevacizumab to Standard Osteosarcoma Therapy

Increased vascular endothelial growth factor (VEGF) expression in osteosarcoma correlates with a poor outcome. We conducted a phase II trial to evaluate the feasibility and efficacy of combining bevacizumab, a monoclonal antibody against VEGF, with methotrexate, doxorubicin and cisplatin (MAP) in pa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Cancer
Hlavní autoři: Navid, Fariba, Santana, Victor M., Neel, Michael, McCarville, M. Beth, Shulkin, Barry L., Wu, Jianrong, Billups, Catherine A., Mao, Shenghua, Daryani, Vinay M., Stewart, Clinton F., Kunkel, Michelle, Smith, Wendene, Ward, Deborah, Pappo, Alberto S., Bahrami, Armita, Loeb, David M., Willert, Jennifer Reikes, Rao, Bhaskar N., Daw, Najat C.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5812455/
https://ncbi.nlm.nih.gov/pubmed/28631382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.30841
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky